What Is Thymosin Alpha-1? Benefits, Research & Safety
A thymic peptide with potent immunomodulatory properties, approved in some countries for treating viral hepatitis and as an immune adjuvant.
UK summary: Not a licensed UK medicine. Licensed in 35+ other countries (Zadaxin) for chronic hepatitis B/C and as an immune adjuvant. UK readers should not conflate 'approved elsewhere' with 'available on the NHS'. Sport status is uncertain — confirm before competition.
Quick Facts
Overview
Thymosin Alpha-1 — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Licensed in 35+ other countries (Zadaxin) for chronic hepatitis B/C and as an immune adjuvant. UK readers should not conflate 'approved elsewhere' with 'available on the NHS'. Sport status is uncertain — confirm before competition.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed. Available through specialist channels in some cases.
- EU: Approved in some member states; orphan drug designation for certain conditions.
- Notes: Thymosin Alpha-1 (Zadaxin) is approved in over 35 countries including China, Philippines, and several European and South American nations. It is not FDA approved in the US. Orphan drug designations exist for certain conditions.
05Approved medical uses
- Chronic hepatitis B and C (licensed as Zadaxin in 35+ countries — NOT MHRA-licensed in the UK).
- Immune-adjuvant in certain cancer treatments (in the licensed jurisdictions).
- Immunocompromised-state support (in the licensed jurisdictions).
06Unapproved / promotional claims
- Boosts immune function in healthy adults.
- Treats long COVID or chronic fatigue syndrome.
- Cures autoimmune disease.
- Safe and effective for general wellness.
07Common internet claims
- Marketed by private 'immune optimisation' clinics for everyday wellness.
- Sold by online retailers as research-only injection.
- Promoted as a long-COVID / chronic-fatigue therapy.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Approved hepatitis treatment with strong safety record” | B | Yes | Moderate | Zadaxin is licensed for chronic hepatitis B/C in many jurisdictions; not licensed in the UK; UK access is not via standard NHS routes. |
| “Boosts immunity for everyday wellness” | E | No | High | Immune-modulator use in healthy adults is not a licensed indication; 'boosts immunity' is a recognised regulatory red-flag phrase. |
| “Cures long COVID / chronic fatigue” | E | No | High | Promising mechanistic interest exists but robust RCT evidence for these specific indications is lacking. |
| “Safe — no serious adverse events” | B | Yes | Moderate | Safety in licensed indications is well documented; caution in autoimmune disease and transplant recipients. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Injection-site reactions.
- Theoretical risk of triggering autoimmune flares.
- Caution required in transplant recipients (immune-stimulation conflict).
- Unknown long-term effects when used outside licensed indications.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Not licensed. Available through specialist channels in some cases.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
Approved in some member states; orphan drug designation for certain conditions.
15What this page cannot tell you
- Whether a UK-purchased vial actually contains TA1 at the labelled concentration.
- Whether immune stimulation in a healthy adult provides any benefit.
- How it interacts with immunosuppressants in transplant or autoimmune patients.
- Whether long COVID or chronic fatigue benefit is real — RCT evidence does not yet exist.
16Last reviewed
17Citation quality score
18Research gaps
- No UK MHRA marketing authorisation despite extensive international use.
- Long COVID and chronic fatigue RCT evidence not yet published.
- Optimal dose / duration in unlicensed indications unestablished.
- Healthy-adult outcomes data effectively absent.
19Safer alternatives / established care pathways
- GP review for any chronic infection, immunodeficiency, or post-viral syndrome.
- Licensed antivirals for hepatitis B and C via NHS hepatology service.
- NHS long-COVID clinic referral (where available) for evidence-based multidisciplinary care.
- Standard vaccination schedule for general immune support.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Thymosin Alpha-1 a licensed UK medicine for any condition?
- If I'm being offered it for an immune indication, is the prescriber registered in the UK and what's the supply chain?
- Are there licensed UK alternatives for my underlying condition?
- What is the WADA / UKAD position if I compete?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Enhanced T cell function and maturation
- 2Improved responses to viral infections (hepatitis B and C)
- 3Vaccine response enhancement
- 4Potential adjuvant effects in cancer therapy
- 5Immune support in immunocompromised states
- 6Possible benefits in sepsis and critical illness
- 7Balanced immunomodulation rather than excessive stimulation
Claim vs Evidence
How popular claims about Thymosin Alpha-1 stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Approved hepatitis treatment with strong safety record” | B | Yes | Moderate | Zadaxin is licensed for chronic hepatitis B/C in many jurisdictions; not licensed in the UK; UK access is not via standard NHS routes. |
| “Boosts immunity for everyday wellness” | E | No | High | Immune-modulator use in healthy adults is not a licensed indication; 'boosts immunity' is a recognised regulatory red-flag phrase. |
| “Cures long COVID / chronic fatigue” | E | No | High | Promising mechanistic interest exists but robust RCT evidence for these specific indications is lacking. |
| “Safe — no serious adverse events” | B | Yes | Moderate | Safety in licensed indications is well documented; caution in autoimmune disease and transplant recipients. |
Theoretical Dosing & Protocols
| Theoretical Dosage | 1.6 mg subcutaneously (standard pharmaceutical dose) |
| Frequency | Twice weekly for most approved indications |
| Duration | Variable depending on indication; often 6-12 months for hepatitis |
| Notes | Thymosin Alpha-1 is an approved medication in several countries. Dosing follows established pharmaceutical protocols. Use should be under medical supervision with appropriate monitoring. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (approved route)
| Half-Life | Stability |
|---|---|
| Approximately 2 hours | Pharmaceutical formulations (Zadaxin) have defined stability; lyophilised forms should be stored appropriately |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions (mild)
- Fatigue
- Mild flu-like symptoms
- Generally very well tolerated
Rare Risks & Concerns
- Allergic reactions (rare)
- Theoretical concerns in autoimmune conditions
- Limited data in pregnancy
Contraindications
- Known hypersensitivity to Thymosin Alpha-1
- Organ transplant recipients (immune stimulation may risk rejection)
- Certain autoimmune conditions (use with caution)
- Pregnancy (limited data)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed. Available through specialist channels in some cases.
🇪🇺 European Union
Approved in some member states; orphan drug designation for certain conditions.
Clinical Studies Summary
Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.
Tα1 can regulate the balance of immune cells and alleviate immune suppression in SAP patients, including increasing CD4+ T cells and CD4+/CD8+ ratios. Tα1 may exert anti-inflammatory and extrapancreatic infection-preventive effects on SAP patients and improve their condition or prognosis. More researches are needed to validate the results.
The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.
Our study suggests that treatment with thymosin alpha-1 may reduce mortality rate in moderate to critical COVID-19 patients. Randomized clinical trials (RCTs) are still required to verify the findings of our study.
The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis.
ETV plus Tα1 might lead to a higher clinical response and a lower comprehensive adverse reaction rate in HBV-related patients with cirrhosis, compared to ETV alone. However, the whole patients included in this meta-analysis were from Chinese mainland, so that more worldwide RCTs with a larger sample size are needed to verify the current findings.
Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection.
We assessed the cumulative findings with trial sequential analysis to control for random errors.
Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials.
Based on substantial evidence from clinical trials, Tα1 emerges as a well-tolerated and effective immune modulator. The FDA›s restriction appears unfounded, as Tα1 has shown safety and efficacy beyond the initially specified conditions. Urgent attention and intervention are warranted to ensure the continued availability of this life-saving peptide through prescription.
Aging and Thymosin Alpha-1.
It represents a promising therapeutic approach to counteract age-related immune dysfunction and inflammation, potentially by slowing the aging process. Further research is needed to validate its long-term efficacy and safety in geriatrics.
Registered Trials & Regulatory Status
15 of 17 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Thymosin-α1 for Recurrent Implantation Failure
Status: Recruiting · 136 participants · Fakih IVF Fertility Center
Conditions: Recurrent Implantation Faliure
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
Status: Recruiting · 52 participants · Beijing Friendship Hospital
Conditions: MCRC
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
Status: Recruiting · 75 participants · The Methodist Hospital Research Institute
Conditions: Vaccine Response, COVID-19 Vaccine, Immune Response to Covid 19 Vaccination
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
Status: Not Yet Recruiting · 40 participants · Xuanwu Hospital, Beijing
Conditions: Resectable Non-Small-Cell Lung Cancer
Immuno-effect of Tα1 for Stage I NSCLC
Status: Recruiting · 40 participants · Yousheng Mao
Conditions: Non Small Cell Lung Cancer
Thymosin Alpha-1 for irAE Secondary to ICIs
Status: Unknown · 40 participants · Jun Wang
Conditions: IrAE
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
Status: Active Not Recruiting · 114 participants · Sun Yat-sen University
Conditions: Non-small Cell Lung Cancer
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
Status: Recruiting · 55 participants · Sun Yat-sen University
Conditions: Melanoma, Immune-related Adverse Event, Immune Checkpoint Inhibitor
Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass
Status: Unknown · 200 participants · Nanjing Medical University
Conditions: Rheumatic Heart Disease, Cardiopulmonary Bypass, Immunotherapy
Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)
Status: Recruiting · 330 participants · Nanjing Medical University
Conditions: Acute Aortic Syndrome, Aortic Dissection Type a
Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder
Status: Completed · 20 participants · Shanghai Public Health Clinical Center
Conditions: HIV-1-infection
Long-term Prognosis of Patients With Sepsis After Immunotherapy
Status: Not Yet Recruiting · 900 participants · Sun Yat-sen University
Conditions: Long-term Effects of Thymosin Alpha 1 Treatment
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Thymosin Alpha-1?
Source research-grade Thymosin Alpha-1 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Thymosin Alpha-1
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Thymosin Alpha-1 a licensed UK medicine for any condition?
- If I'm being offered it for an immune indication, is the prescriber registered in the UK and what's the supply chain?
- Are there licensed UK alternatives for my underlying condition?
- What is the WADA / UKAD position if I compete?
UK regulatory & safety context
Related Research Guides
Related Peptides
TB-500
A synthetic version of the naturally occurring peptide Thymosin Beta-4, extensively researched for its roles in tissue repair, cell migration, and angiogenesis.
Learn moreThymosin Beta-4
A 43-amino acid peptide naturally present in all cells, fundamental to tissue repair, cell migration, and regeneration processes throughout the body.
Learn moreLL-37
The only human cathelicidin antimicrobial peptide, with broad-spectrum antimicrobial activity and important immunomodulatory functions.
Learn more